<DOC>
	<DOCNO>NCT01639521</DOCNO>
	<brief_summary>This study two chemotherapy study drug combination ( regimen ) use urothelial ( bladder upper urinary tract ) cancer . Both study drug regimen , gemcitabine ( gemcitabine hydrochloride ) plus cisplatin , high-dose-intensity MVAC ( methotrexate , vinblastine , doxorubicin plus cisplatin ) , standard chemotherapy regimen . Both regimen use treat people urothelial cancer spread organ . Both study drug regimen proven effective lower risk cancer come back , know regimen best . This study hop learn whether difference effectiveness side effect two study drug regimen give people urothelial cancer completely remove .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride Cisplatin High-Dose Methotrexate , Vinblastine , Doxorubicin Hydrochloride , Cisplatin Treating Patients With Urothelial Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES To estimate difference rate unacceptable toxicity dose-dense methotrexate , vinblastine , doxorubicin , cisplatin ( MVAC ) gemcitabine cisplatin ( GC ) adjuvant treatment urothelial cancer . SECONDARY OBJECTIVES To compare rate disease recurrence 3 year dose-dense MVAC GC . To determine whether molecular marker excision repair cross-complementing-1 ( ERCC-1 ) ribonucleoside-diphosphate reductase M-1 ( RRM-1 ) , breast cancer 1 ( BRCA1 ) topoisomerase 2-alpha ( Top2A ) protein 53 ( p53 ) predict patient likely benefit chemotherapy . To investigate potential utility cytidine deaminase ( CDA ) , ERCC-1 , xeroderma pigmentosum group D ( XPD ) , glutathione S-transferase P-1 ( GSTP-1 ) glutathione S-transferase M-1 ( GSTM-1 ) molecular marker predict occurrence significant toxicity adjuvant chemotherapy urothelial cancer . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive cisplatin intravenously ( IV ) day 1 gemcitabine hydrochloride IV 1 hour day 1 8 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . ARM B : Patients receive methotrexate IV day 1 , vinblastine IV , doxorubicin hydrochloride IV , cisplatin IV day 2 pegfilgrastim subcutaneously ( SC ) day 3 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically confirm highgrade urothelial carcinoma , stage T3bN0 , T4N0 T stage lymph node involvement , completely resect ; include upper tract urothelial carcinoma The dominant histology must transitional cell urothelial focus histology less 20 percent total tumor volume permit Absence metastatic disease radiographic imaging Patients must enrol able start treatment within 90 day radical cystectomy radical nephrectomy Creatinine le institutional upper limit normal ( ULN ) clearance great equal 50 mL/min ( may calculate CockcroftGault formula measure 24hour urine collection ) Serum total bilirubin less equal 1.5 x ULN ( except patient Gilbert 's ) Alkaline phosphatase less equal 2.5 x ULN Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvate transaminase ( SGPT ) less equal 2.5 x ULN White blood cell ( WBC ) great equal 3000 Absolute neutrophil count ( ANC ) great equal 1500 Hemoglobin ( Hb ) great equal 9 Platelets great equal 100,000 Normal leave ventricular ejection fraction , echocardiogram multi gate acquisition scan ( MUGA ) Patients must recover surgery Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Willing able provide inform consent Willingness use barrier contraception study period The presence significant pleural effusion ascites Prior systemic chemotherapy urothelial carcinoma include neoadjuvant chemotherapy ( prior intravesical therapy permit ) History malignancy within precede 5 year , aside nonmelanoma skin cancer previously treat incidentally detected prostate cancer undetectable PSA ( radical cystectomy prostate cancer therapy ) Peripheral neuropathy great grade 1 The presence active heart disease congestive heart failure unstable angina</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>